Global Cancer Gene Therapy Market Report and Forecast 2024-2032

Global Cancer Gene Therapy Market Overview

Cancer gene therapy works by changing and substituting defective genes to treat or prevent cancer. The market is experiencing rapid growth, driven by CRISPR-9, rising cancer rates, and advancements in personalized medicine. Other market trends involve the integration of AI for enhanced diagnosis and increased funding to promote innovation. These various characteristics are expanding the market by offering effective solutions for previously unaddressed needs, which in turn improves research and development and promotes commercialization.

Global Cancer Gene Therapy Market Growth Drivers

Rising Prevalence of Cancer Drives Market Growth

Due to the rising number of cancer cases worldwide, there is a growing need for new, advanced treatments. According to the American Cancer Society, 1,958,310 new cancer cases were detected, and 609,820 cancer fatalities took place in the United States in 2023. Gene therapy provides personalized and targeted treatments, addressing areas where traditional therapies are ineffective. Hence, the increasing number of patients is boosting market growth by motivating research and development as well as commercialization activities.

Global Cancer Gene Therapy Market Trends

Global Cancer Gene Therapy Market Segmentation

Global Cancer Gene Therapy Market Share

Market Segmentation Based on the Indication Set to Witness Substantial Growth

Based on indication, the market is segmented into breast cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, prostate cancer, and others. Among these, breast cancer is the leading cancer type in the market because of its rising global incidence and the growing emphasis on targeted therapy solutions. Gene therapies for breast cancer target genetic mutations, providing personalized and efficient treatments. This led to significant funding in R&D, leading to many clinical trials and approvals.

Global Cancer Gene Therapy Market Analysis by Region

Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America is projected to lead the market due to the presence of large pharmaceutical companies and significant healthcare spending. Strong research endeavors and support from the government for cancer research are helping to grow the local market.

Leading Players in the Global Cancer Gene Therapy Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Bristol-Myers Squibb Company

Based in New York, the company holds a significant presence in the immuno-oncology research domain. One of their notable products include Abecma (idecabtagene vicleucel) is a CAR T-cell therapy approved for treating relapsed or refractory multiple myeloma in the field of cancer gene therapy.

Elevate Bio Inc.

Elevate Bio Inc. is an international biotech corporation that focuses on cell and gene treatments. The headqua...

Abeona Therapeutics Inc.

The company was established in New York and is in the process of creating cell and gene therapies for severe i...

Bluebird Bio Inc.

Bluebird Bio Inc. is an international biotech company headquartered in Massachusetts. In partnership with Bris...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include Asklepios BioPharmaceutical Inc., NantKwest, Inc., Glaxo Smith Kline Inc., and Genelux Corporation.

Key Questions Answered in the Global Cancer Gene Therapy Market

• What was the global cancer gene therapy market value in 2023?
• What is the global cancer gene therapy market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is the market segmentation based on the therapy type?
• What is the market breakup based on the indication?
• What is the market breakup based on the end user?
• What are the major factors aiding the cancer gene therapy market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major cancer gene therapy market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the cancer gene therapy market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• How does oncolytic virotherapy work in treating cancer?
• Which cancer indication dominates the cancer gene therapy market?
• Why are hospitals significant end-users of cancer gene therapy?
• How is the Asia Pacific region contributing to the growth of the cancer gene therapy market?